ASTRAZENECA PLCAZN

時価総額

PER

革新的医薬品の最大手。がん、循環器、希少疾患向けのバイオ医薬品や放射性標的治療を展開。2024年6月にFusionを2,195百万ドルで買収。2024年の製品売上は50,938百万ドル、80カ国超で展開。

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Profit before tax	2,227	1,993	1,548	3,916	-265	2,501	6,899	8,691
Finance income and expense	-	-	-	-	-	-	-1,282	-1,284
Share of after tax losses of associates and joint ventures	-	-	-	-	-	-	-12	-28
Depreciation, amortisation and impairment	-	-	-	-	-	-	5,387	6,688
Increase in trade and other receivables	83	-523	-898	-739	-961	-1,349	-1,425	-1,624
(Increase)/decrease in inventories	-548	-13	-316	-621	1,577	3,941	-669	-131
Increase in trade and other payables and provisions	-415	103	-868	-1,721	-1,405	-1,165	-2,394	-862
Gains on disposal of intangible assets	-1,518	-1,885	-1,243	-1,030	-513	-104	-251	-64
Contingent consideration, fair value movement	109	-495	-614	-272	14	82	549	311
Non-cash and other movements	-524	-290	378	-276	95	-692	-386	-121
Cash generated from operations	4,730	3,831	4,861	7,094	8,427	12,280	13,792	15,924
Interest paid	698	676	774	733	721	849	1,081	1,313
Tax paid	454	537	1,118	1,562	1,743	1,623	2,366	2,750
Net cash inflow from operating activities	3,578	2,618	2,969	4,799	5,963	9,808	10,345	11,861
Acquisition of subsidiaries, net of cash acquired	-	-	-	-	9,263	48	189	2,771
Payments upon vesting of employee share awards attributable to business combinations	-	-	-	-	211	215	84	3
Payment of contingent consideration from business combinations	434	349	709	822	643	772	826	1,008
Purchase of property, plant and equipment	1,326	1,043	979	961	1,091	1,091	1,361	1,924
Disposal of property, plant and equipment	83	12	37	106	13	282	132	55
Purchase of intangible assets	294	328	1,481	1,645	1,109	1,480	2,417	2,662
Disposal of intangible assets	1,376	2,338	2,076	951	587	-	291	123
Movement in profit-participation liability	-	-	150	40	20	-	190	-
Purchase of non-current asset investments	96	102	13	119	184	45	136	96
Disposal of non-current asset investments	70	24	18	1,381	9	42	32	78
Other inflows (outflows) of cash, classified as investing activities	-345	405	194	745	96	-114	97	30
Payments to associates and joint ventures	76	187	74	8	92	26	80	158
Disposal of investments in associates and joint ventures	-	-	-	-	776	-	-	13
Interest received	164	193	124	47	34	60	287	343
Net cash outflow from investing activities	-2,328	963	-657	-285	-11,058	-2,960	-4,064	-7,980
Net cash inflow before financing activities	1,250	3,581	2,312	4,514	-5,095	6,848	6,281	3,881
Proceeds from issuing shares	43	34	3,525	30	29	29	33	38
Own shares purchased by Employee Benefit Trusts	-	-	-	-	149	-	-	81
Issue of loans and borrowings	1,988	2,971	500	2,968	12,929	-	3,816	6,492
Repayment of loans and borrowings	1,750	1,400	1,500	1,609	4,759	1,271	4,942	4,652
Dividends paid	3,519	3,484	3,592	3,572	3,856	4,364	4,481	4,629
Hedge contracts relating to dividend payments	20	67	-4	101	29	127	19	-16
Repayment of obligations under leases	-	-	186	207	240	244	268	316
Movement in short-term borrowings	-	-	-	-	-	-	-	-31
Payment of Acerta Pharma share purchase liability	-	-	-	-	-	920	867	833
Net cash outflow from financing activities	-2,936	-2,044	-1,765	-2,203	3,649	-6,823	-6,567	-3,996
Net (decrease)/increase in Cash and cash equivalents in the period	-1,686	1,537	547	2,311	-1,446	25	-286	-115
Exchange rate effects	-66	-38	5	12	-62	-80	-60	-93